234 related articles for article (PubMed ID: 28361850)
1. Prognostic value of the bone turnover markers in multiple myeloma.
Auzina D; Erts R; Lejniece S
Exp Oncol; 2017 Mar; 39(1):53-56. PubMed ID: 28361850
[TBL] [Abstract][Full Text] [Related]
2. [Clinical characteristics of bone disease in multiple myeloma and clinical significance of monitoring bone metabolic markers].
Chu B; Lu MQ; Wu MQ; Shi L; Fu LN; Gao S; Fang LJ; Xiang QQ; Bao L
Zhonghua Yi Xue Za Zhi; 2016 May; 96(18):1424-9. PubMed ID: 27266350
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis.
Lund T; Abildgaard N; Andersen TL; Delaisse JM; Plesner T
Eur J Haematol; 2010 May; 84(5):412-20. PubMed ID: 20070853
[TBL] [Abstract][Full Text] [Related]
4. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
[TBL] [Abstract][Full Text] [Related]
5. Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?
Søe K; Plesner T; Jakobsen EH; Hansen CT; Jørgensen HB; Delaissé JM
J Bone Miner Res; 2013 Aug; 28(8):1738-50. PubMed ID: 23427025
[TBL] [Abstract][Full Text] [Related]
6. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study.
Garnero P; Cloos P; Sornay-Rendu E; Qvist P; Delmas PD
J Bone Miner Res; 2002 May; 17(5):826-33. PubMed ID: 12009013
[TBL] [Abstract][Full Text] [Related]
7. Activity or mass concentration of bone-specific alkaline phosphatase as a marker of bone formation.
Avbersek-Luznik I; Gmeiner Stopar T; Marc J
Clin Chem Lab Med; 2007; 45(8):1014-8. PubMed ID: 17579570
[TBL] [Abstract][Full Text] [Related]
8. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
[TBL] [Abstract][Full Text] [Related]
9. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
[TBL] [Abstract][Full Text] [Related]
10. [Some bone turnover markers in serum of healthy children and adolescents in relation to age and gender].
Gajewska J; Ambroszkiewicz J; Laskowska-Klita T
Wiad Lek; 2005; 58(9-10):476-80. PubMed ID: 16529055
[TBL] [Abstract][Full Text] [Related]
11. Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years.
Rauchenzauner M; Schmid A; Heinz-Erian P; Kapelari K; Falkensammer G; Griesmacher A; Finkenstedt G; Högler W
J Clin Endocrinol Metab; 2007 Feb; 92(2):443-9. PubMed ID: 17105843
[TBL] [Abstract][Full Text] [Related]
12. Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer.
Søe K; Delaissé JM; Jakobsen EH; Hansen CT; Plesner T
Acta Oncol; 2014 Apr; 53(4):547-56. PubMed ID: 24164102
[TBL] [Abstract][Full Text] [Related]
13. Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients.
Bielesz BO; Hecking M; Plischke M; Cejka D; Kieweg H; Haas M; Marculescu R; Hörl WH; Bieglmayer C; Sunder-Plassmann G
Clin Biochem; 2014 Sep; 47(13-14):1316-9. PubMed ID: 24956265
[TBL] [Abstract][Full Text] [Related]
14. Serological bone markers and joint damage in early polyarthritis.
Jansen LM; van der Horst-Bruinsma I; Lems WF; van Schaardenburg D; van de Stadt R; de Koning M; Dijkmans BA
J Rheumatol; 2004 Aug; 31(8):1491-6. PubMed ID: 15290726
[TBL] [Abstract][Full Text] [Related]
15. Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms.
Magnusson P; Sharp CA; Magnusson M; Risteli J; Davie MW; Larsson L
Kidney Int; 2001 Jul; 60(1):257-65. PubMed ID: 11422759
[TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of the ratio of serum beta-CTX/PINP in multiple myeloma bone diseases and bone metastases].
Yang SW; Ma RJ; Zhao JJ; Yuan XL; Jiang L; Yang J; Lei PC; Zhang Y; Zhang L; Liu G; Wang F; Zhu ZM
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2583-2587. PubMed ID: 30220144
[No Abstract] [Full Text] [Related]
17. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
Ebert W; Muley T; Herb KP; Schmidt-Gayk H
Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance of serum bone metabolic markers in diagnosis and monitoring of myeloma bone disease].
Peng F; Fu R; Liu H; Wang Y; Ding K; Ding S; Liu Z; Ruan E; Qu W; Wang H; Xing L; Wang X; Wang G; Song J; Wu Y; Li L; Liu H; Guan J; Shao Z
Zhonghua Yi Xue Za Zhi; 2015 Nov; 95(42):3436-9. PubMed ID: 26813134
[TBL] [Abstract][Full Text] [Related]
19. The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group.
Terpos E; Christoulas D; Kastritis E; Katodritou E; Papatheodorou A; Pouli A; Kyrtsonis MC; Michalis E; Papanikolaou X; Gkotzamanidou M; Koulieris E; Gavriatopoulou M; Zervas K; Dimopoulos MA;
Am J Hematol; 2014 Jan; 89(1):34-40. PubMed ID: 23983166
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study.
Garnero P; Peterfy C; Zaim S; Schoenharting M
Arthritis Rheum; 2005 Sep; 52(9):2822-9. PubMed ID: 16145678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
